KEAPSTONE

KEAPSTONE THERAPEUTICS is developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS)... We are developing CNS penetrant, non-reactive small molecules that prevent KEAP1 from interacting with Nrf2

Also known as: Keapstone Therapeutics Limited

Primary location: Sheffield United Kingdom